FDA approves Rebyota, Ferring's poop-based drug to fight C. diff infection
The FDA approved Ferring Pharmaceuticals’ Rebyota drug on Wednesday, a poop-based drug implant that can prevent the recurrence of Clostridioides difficile infection.
While the use of fecal microbiota transplantation (FMT) — replenishing a patient’s gut with bacteria from healthy feces — has already been happening without an FDA-approved product, Rebyota is the first live biotherapeutic drug approved by the agency to fight the potentially deadly infection.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.